Publication
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
Publisher:
Springer Science and Business Media LLC
Date:
09-06-2021
DOI:
10.1007/S00280-021-04296-0
Abstract: To characterize pertuzumab pharmacokinetics (PK) in FeDeriCa (NCT03493854: fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection [PH FDC SC] versus intravenous pertuzumab plus trastuzumab) derive in idual pertuzumab exposures in the PH FDC SC arm for subsequent pertuzumab exposure–response (ER) analyses compare observed trastuzumab PK with predicted exposures from a previous SC trastuzumab model assess whether pertuzumab affects trastuzumab PK evaluate pertuzumab exposure–efficacy and –safety relationships and support the approved SC dosing regimen. Population pharmacokinetic modeling and simulations were used to describe the data. Standard goodness-of-fit diagnostics and prediction-corrected visual predictive checks were used for model performance assessment. Covariates were included from previously reported models. ER analysis was conducted using logistic regression. SC pertuzumab PK was described adequately by a two-compartment model with first-order absorption significant covariates included in the final model were albumin, lean body weight, and Asian region however, these appeared not to be clinically relevant. Trastuzumab concentrations were described adequately by the previous model there was no evidence of a pertuzumab effect on trastuzumab PK as part of PH FDC SC and higher model-predicted pertuzumab exposure was not associated with differences in pathologic complete response rate or an increased probability of selected grade ≥ 3 adverse events of interest. The approved PH FDC SC dose [loading: 1200/600 mg pertuzumab/trastuzumab (15 mL) maintenance: 600 mg pertuzumab/trastuzumab (10 mL) and 2000 U/mL recombinant human hyaluronidase every 3 weeks] provides a positive benefit–risk profile with comparable efficacy and safety to intravenous pertuzumab plus trastuzumab.